TYK2 as a novel therapeutic target in Alzheimer’s Disease with TDP-43 inclusions
Authored by
Laura E. König, Steve Rodriguez, Clemens Hug, Shayda Daneshvari, Alexander Chung, Gary A. Bradshaw, Asli Sahin, George Zhou, Robyn J. Eisert, Federica Piccioni, Sudeshna Das, Marian Kalocsay, Artem Sokolov, Peter Sorger, David E. Root, and Mark W. Albers
Posted
June 6, 2024
Server
bioRxiv
Abstract
SUMMARY Neuroinflammation is a pathological feature of many neurodegenerative diseases, including Alzheimer’s disease (AD)1,2 and amyotrophic lateral sclerosis (ALS)3 , raising the possibility of common therapeutic targets. We previously established that cytoplasmic double-stranded RNA (cdsRNA) is spatially coincident with cytoplasmic pTDP-43 inclusions in neurons of patients with C9ORF72-mediated ALS4 . CdsRNA triggers a type-I interferon (IFN-I)-based innate immune response in human neural cells, resulting in their death4 . Here, we report that cdsRNA is also spatially coincident with pTDP-43 cytoplasmic inclusions in brain cells of patients with AD pathology and that type-I interferon response genes are significantly upregulated in brain regions affected by AD. We updated our machine-learning pipeline DRIAD-SP (Drug Repurposing In Alzheimer’s Disease with Systems Pharmacology) to incorporate cryptic exon (CE) detection as a proxy of pTDP-43 inclusions and demonstrated that the FDA-approved JAK inhibitors baricitinib and ruxolitinib that block interferon signaling show a protective signal only in cortical brain regions expressing multiple CEs. Furthermore, the JAK family member TYK2 was a top hit in a CRISPR screen of cdsRNA-mediated death in differentiated human neural cells. The selective TYK2 inhibitor deucravacitinib, an FDA-approved drug for psoriasis, rescued toxicity elicited by cdsRNA. Finally, we identified CCL2, CXCL10, and IL-6 as candidate predictive biomarkers for cdsRNA-related neurodegenerative diseases. Together, we find parallel neuroinflammatory mechanisms between TDP-43 associated-AD and ALS and nominate TYK2 as a possible disease-modifying target of these incurable neurodegenerative diseases.
Read the preprint
